Uncertainties in climatic conditions and the increasing exposure to ultraviolet radiation are unusual factors that trigger skin cancer incidence in various countries. However, mortality due to skin cancer is reducing in the region due to the continuously growing awareness regarding skin cancer. Also, increasing access to self-examination and screening tests simplifies the detection of skin cancer among people. The surge in awareness is primarily attributed to the support provided by various governments through awareness and prevention campaigns. The Centers for Disease Control and Prevention (CDC) and its partners conduct monitoring of skin cancer cases, their research, provide education, and interventions for skin cancer. The monitoring is achieved through national surveys, such as the Youth Risk Behavior Surveillance System and National Health Interview Survey. These surveys assist in assessing the prevalence of sunburn and sun-protective behaviors to help prevent skin cancer. Thus, governments’ efforts to control mortalities associated with skin cancer will likely provide significant opportunities to the Asia Pacific skin cancer diagnostics market players in the coming years.
With the new features and technologies, vendors attract new customers and expand their footprints in emerging markets. This factor is driving the growth of Asia Pacific skin cancer diagnostics market at a promising CAGR.
Skin cancer diagnostics market is segmented into type and screening type. Based on type, the market is segmented into melanoma and non-melanoma. Based on screening type, the market is segmented into skin biopsy, dermatoscopy, lymph node biopsy, imaging tests, and blood tests. Based on country, the market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific.
AMLo Biosciences Limited; DermLite LLC; bioMerieux SA; Hoffmann-La Roche Ltd.; and Michelson Diagnostics Ltd. are among the leading companies in the Asia Pacific skin cancer diagnostics market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 660.1 Million |
| Market Size by 2028 | US$ 1,197.4 Million |
| CAGR (2021 - 2028) | 8.9% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Skin Cancer Diagnostics Market is valued at US$ 660.1 Million in 2021, it is projected to reach US$ 1,197.4 Million by 2028.
As per our report Asia Pacific Skin Cancer Diagnostics Market, the market size is valued at US$ 660.1 Million in 2021, projecting it to reach US$ 1,197.4 Million by 2028. This translates to a CAGR of approximately 8.9% during the forecast period.
The Asia Pacific Skin Cancer Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Skin Cancer Diagnostics Market report:
The Asia Pacific Skin Cancer Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Skin Cancer Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Skin Cancer Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Skin Cancer Diagnostics Market
